TrialThe British journal of dermatology2022

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.

K Kabashima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.